Recently approved heart drug poses potential risk to brain & eye, Temple researcher warns

(Temple University Health System) Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, M.D., Ph.D., Executive Dean of the Lewis Katz School of Medicine at Temple University.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news